VKTX
VKTX
NASDAQ · Biotechnology

Viking Therapeutics Inc

$32.17
-0.38 (-1.17%)
As of Mar 24, 10:00 PM ET ·
Financial Highlights (FY 2025)
Revenue
1.82B
Net Income
202.06M
Gross Margin
59.7%
Profit Margin
11.1%
Rev Growth
+17.6%
D/E Ratio
0.22
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 59.7% 59.7% 59.7%
Operating Margin 11.9% 11.4% 11.4%
Profit Margin 11.1% 12.3% 8.7%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 1.82B 1.78B 1.68B
Gross Profit 1.09B 1.07B 1.01B
Operating Income 216.49M 202.71M 192.05M
Net Income 202.06M 220.26M 147.13M
Gross Margin 59.7% 59.7% 59.7%
Operating Margin 11.9% 11.4% 11.4%
Profit Margin 11.1% 12.3% 8.7%
Rev Growth +17.6% -0.7% +11.4%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 472.05M 471.52M 492.96M
Total Equity 2.11B 2.01B 2.12B
D/E Ratio 0.22 0.23 0.23
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 246.26M 251.94M 230.42M
Free Cash Flow 210.43M 219.41M 153.78M